Article
Oncology
Mohammad Naghavi-Behzad, Marianne Vogsen, Rasmus Molgard Vester, Maiken Madsen Bjerregaard Olsen, Hjalte Oltmann, Poul-Erik Braad, Jon Thor Asmussen, Oke Gerke, Werner Vach, Kristian Kidholm, Annette Raskov Kodahl, Wolfgang Weber, Malene Grubbe Hildebrandt
Summary: This study compared the use of CE-CT, FDG-PET/CT, or a combination of both in monitoring metastatic breast cancer patients. The results showed that patients monitored with FDG-PET/CT alone or in combination with CE-CT had longer overall survival and earlier detection of disease progression.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Alexander Brose, Kerstin Michalski, Juri Ruf, Marco Tosch, Susanne M. Eschmann, Mathias Schreckenberger, Jochem Koenig, Ursula Nestle, Matthias Miederer
Summary: The aim of this study was to evaluate and compare visual and threshold-based semi-automated evaluation criteria for the assessment of suspected tumor recurrence. The results showed that visual assessment, especially with high reader certainty, had high interobserver agreement and accuracy, and could be further improved by baseline PET/CT information.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jonathan Moore, Manil Subesinghe, Aida Santaolalla, Michael Green, Harriet Deere, Mieke Van Hemelrijck, Jesper Lagergren, Sugama Chicklore, Nick Maisey, James Gossage, Mark Kelly, Cara Baker, Andrew Davies
Summary: This study evaluated the role of FDG PET-CT in predicting pathological tumor response, nodal response, and survival in neoadjuvant therapy for esophageal cancer. The study found that metabolic tumor and nodal response can predict pathological tumor response and nodal response, and these responses are independent predictors of patient survival.
EUROPEAN RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Leigh C. Casadaban, Paul J. Catalano, Leslie K. Lee, Hyewon Hyun, Kemal Tuncali, Victor H. Gerbaudo, Paul B. Shyn
Summary: The study retrospectively assessed liver tumor ablation margins using intraprocedural PET/CT images and correlated minimum margin measurements with local progression outcomes. Results showed that intraprocedural PET/CT was more reliable than postprocedural MRI, and a minimum ablation margin < 5 mm was associated with an increased risk of local tumor progression.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Multidisciplinary Sciences
Mohammad Naghavi-Behzad, Oke Gerke, Annette Raskov Kodahl, Marianne Vogsen, Jon Thor Asmussen, Wolfgang Weber, Malene Grubbe Hildebrandt, Kristian Kidholm
Summary: This study evaluated the cost-effectiveness of 2-[F-18]FDG-PET/CT compared to CE-CT for response monitoring in metastatic breast cancer patients. The findings suggest that 2-[F-18]FDG-PET/CT is a cost-effective modality, particularly in patients with favorable prognostic factors, while CE-CT may be more cost-effective for poor prognosis patients.
SCIENTIFIC REPORTS
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Adrien Holzgreve, Matthias P. Fabritius, Thomas Knoesel, Bernhard W. Renz, Lars H. Lindner, Dorit Di Gioia, Peter Bartenstein, Johannes Ruebenthaler, Reinhold Tiling
Summary: This case study highlights the treatment process of a 38-year-old woman with a rare perivascular epithelioid cell tumor of the gastrointestinal tract, demonstrating both the role and limitations of F-18-FDG PET/CT in monitoring disease progression.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Oncology
Mohammad Naghavi-Behzad, Hjalte Rasmus Oltmann, Tural Asgharzadeh Alamdari, Jakob Lykke Bulow, Lasse Ljungstrom, Poul-Erik Braad, Jon Thor Asmussen, Marianne Vogsen, Annette Raskov Kodahl, Oke Gerke, Malene Grubbe Hildebrandt
Summary: This study compared the response categories and impacts on treatment decisions for metastatic breast cancer patients monitored with CE-CT or FDG-PET/CT. The results showed that FDG-PET/CT indicated regression of disease more frequently than CE-CT, suggesting it may be a more suitable imaging modality for monitoring treatment response in metastatic breast cancer.
Review
Medicine, General & Internal
Jeremy McGale, Sakshi Khurana, Alice Huang, Tina Roa, Randy Yeh, Dorsa Shirini, Parth Doshi, Abanoub Nakhla, Maria Bebawy, David Khalil, Andrew Lotfalla, Hayley Higgins, Amit Gulati, Antoine Girard, Francois-Clement Bidard, Laurence Champion, Phuong Duong, Laurent Dercle, Romain-David Seban
Summary: HER2-positive breast cancer, characterized by amplification of the HER2 gene, is associated with aggressive tumor growth, increased metastatic risk, and poorer prognosis compared to other subtypes. HER2 expression is a crucial tumor feature for breast cancer diagnosis and treatment. Advancements in HER2 in vivo imaging techniques like PET and SPECT may enhance the role of HER2 status in guiding breast cancer management, enabling determination of tumor size, location, and evaluation of treatment effectiveness. This review explores the current and future role of HER2 imaging in personalized care for breast cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E. Gray, Evangelia Katsoulakis, Jie Tian, Robert J. Gillies, Matthew B. Schabath
Summary: The study suggests that quantitative imaging can serve as an alternative to immunohistochemistry for predicting PD-L1 expression status in NSCLC patients treated with immune checkpoint inhibitors. The developed deeply learned score was able to accurately predict durable clinical benefit, progression-free survival, and overall survival in retrospective and prospective cohorts of patients. The findings support the use of this score as a surrogate for PD-L1 measurement in guiding individual treatment decisions.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Nadav Michaan, Atalia Wenkert, Einat Even-Sapir, Kosta Kerzhner, Tatiana Rabin, Tamar Safra, Shira Peleg-Hasson, Yoav Baruch, Yael Raz, Dan Grisaru, Ido Laskov
Summary: This study investigated the prognostic significance of near-complete metabolic response on initial follow-up PET/CT after primary chemoradiation treatment of cervical cancer. The results showed that patients who had near-complete metabolic response on the first PET/CT and later showed complete metabolic response at subsequent PET/CT had significantly fewer cases of recurrence and death compared to those who had complete metabolic response on the first follow-up PET/CT.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Biochemistry & Molecular Biology
Chien-Yi Liao, Jun-Hsuang Jen, Yi-Wei Chen, Chien-Ying Li, Ling-Wei Wang, Ren-Shyan Liu, Wen-Sheng Huang, Chia-Feng Lu
Summary: This study aimed to compare image features extracted from F-18-FBPA PET/CT and PET/MR. The findings showed that most features exhibited strong comparability between the two modalities, particularly conventional features as well as histogram and texture features.
Review
Oncology
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, Kamal Al-Rabi, Mohammad Ma'koseh, Hikmat Abdel-Razeq, Asem Mansour
Summary: Cancer immunotherapy is a cancer treatment that utilizes the immune system to fight against cancer cells. This review aims to discuss the effects and side effects of cancer immunotherapy, and correlate them with the proposed criteria and relevant patterns of FDG PET/CT in lymphoma immunotherapy. Additionally, the latest updates and future prospects will be explored.
Review
Oncology
Bettina Beuthien-Baumann, Christos Sachpekidis, Regula Gnirs, Oliver Sedlaczek
Summary: This review discusses the possible advantages and methods of applying combined imaging protocols of PET-CT and PET-MRI in staging and restaging patients under immunotherapy to achieve multi-hybrid imaging in a single visit. Despite the relatively long acquisition times of PET-MRI scans, they have the potential to provide superb soft tissue contrast and functional information, although not as widely used in oncologic imaging as PET-CT.
Review
Medicine, General & Internal
Anita Brink, Khanyisile N. Hlongwa, Stuart More
Summary: This review paper discusses the use of PET/CT in paediatric oncology, emphasizing its usefulness in accurately staging disease and determining the metabolic response to treatment. It also highlights specific considerations in lymphoma, neuroblastoma, sarcomas, and Langerhans-cell Histiocytosis (LCH) in the paediatric population.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Huipan Liu, Xiao Yang, Dongmei Fan, Taiyong Lv, Yue Chen
Summary: Inflammatory myofibroblastic tumor is a rare mesenchymal neoplasm that can be found in various anatomical regions. This case report presents the Ga-68-FAPI PET/CT findings in a 49-year-old man with mesenteric inflammatory myofibroblastic tumor.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Susan Notohamiprodjo, Stephan G. Nekolla, Stephanie Robu, Alberto Villagran Asiares, Christian Kupatt, Tareq Ibrahim, Karl-Ludwig Laugwitz, Marcus R. Makowski, Markus Schwaiger, Wolfgang A. Weber, Zohreh Varasteh
Summary: This study demonstrated the feasibility of noninvasive imaging of fibroblast activation protein (FAP) expression after myocardial infarction (MI) using Ga-68-FAPI-04-PET, and showed that Ga-68-FAPI-04 uptake extends beyond the actual infarcted area in the infarct territory. Follow-up CMR confirmed the overestimation of the infarct size by Ga-68-FAPI-04 uptake.
JOURNAL OF NUCLEAR CARDIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Nicolo Capobianco, Ludovic Sibille, Maythinee Chantadisai, Andrei Gafita, Thomas Langbein, Guenther Platsch, Esteban Lucas Solari, Vijay Shah, Bruce Spottiswoode, Matthias Eiber, Wolfgang A. Weber, Nassir Navab, Stephan G. Nekolla
Summary: This study developed a deep learning method that improved the accuracy and efficiency of prostate cancer staging by using training data from different radiotracers.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thomas Langbein, Alexander Wurzer, Andrei Gafita, Andrew Robertson, Hui Wang, Ayca Arcay, Michael Herz, Hans-Juergen Wester, Wolfgang A. Weber, Matthias Eiber
Summary: This study found that the time between synthesis and injection and the decrease in specific activity of F-18-rhPSMA-7.3 had only minor effects on its biodistribution in patients. This suggests that F-18-labeled PSMA ligands can be produced centrally and shipped to PET clinics similar to F-18-FDG.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann, Wolfgang A. Weber
Summary: Vaccine-associated lymphadenopathy (VAL) is commonly observed in F-18-rhPSMA-7.3 PET examinations after COVID-19 vaccination. The uptake of PSMA ligand F-18-rhPSMA-7.3 by axillary lymph nodes increases after vaccination and can persist for up to 8 weeks. Moreover, metastatic axillary lymph nodes show a high SUVratio.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Carolin Kitzberger, Rebekka Spellerberg, Volker Morath, Nathalie Schwenk, Kathrin A. Schmohl, Christina Schug, Sarah Urnauer, Mariella Tutter, Matthias Eiber, Franz Schilling, Wolfgang A. Weber, Sibylle Ziegler, Peter Bartenstein, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Summary: The cloning of the sodium iodide symporter (NIS) has opened up new possibilities for gene therapy. Progress has been made in the development of non-viral gene delivery vehicles and monitoring NIS expression using high resolution PET imaging. These advancements have the potential to improve the effectiveness of NIS gene therapy in targeting tumors.
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrei Gafita, Isabel Rauscher, Wolfgang P. Fendler, Vishnu Murthy, Wang Hui, Wesley R. Armstrong, Ken Herrmann, Wolfgang A. Weber, Jeremie Calais, Matthias Eiber, Manuel Weber, Matthias R. Benz
Summary: The purpose of this study is to compare the differences and reliabilities among different criteria for response evaluation using PSMA-PET/CT in men with mCRPC treated with Lu-177-PSMA. The results showed that PSMA-PET-specific criteria achieved better performance in predicting the risk of death and identifying PD vs no-PD.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Editorial Material
Oncology
Wolfgang A. Weber, Zohreh Varasteh, Katja Fritschle, Volker Morath
Summary: FAP-targeted therapies have shown limited success so far, but FAP imaging offers new opportunities for patient selection and monitoring tumor response.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sylvie Lorenzen, Michael Quante, Isabel Rauscher, Julia Slotta-Huspenina, Wilko Weichert, Marcus Feith, Helmut Friess, Stefanie E. Combs, Wolfgang A. Weber, Bernhard Haller, Martin Angele, Markus Albertsmeier, Christiane Blankenstein, Stefan Kasper, Roland M. Schmid, Florian Bassermann, Markus Schwaiger, Sven-Thorsten Liffers, Jens T. Siveke
Summary: This study aimed to differentiate responders and non-responders in patients with locally advanced gastroesophageal junction adenocarcinomas using PET scanning after induction chemotherapy. The primary objective was to improve the R0 resection rates in non-responders. The results showed that PET response was prognostic for overall survival and disease-free survival, but the goal of increasing R0 resection rates in non-responders was not achieved.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kaelin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, Rainer Glass, Wolfgang A. Weber, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Summary: In this study, genetically engineered MSCs carrying the NIS gene were injected into mice to treat experimental glioblastoma. The results showed that NIS-MSCs successfully homed to the tumor and expressed the NIS gene, and subsequent treatment with therapeutically effective radioiodide (131I) significantly delayed tumor growth and prolonged mouse survival.
CLINICAL CANCER RESEARCH
(2023)
Review
Urology & Nephrology
Robert Seifert, Louise Emmett, Steven P. Rowe, Ken Herrmann, Boris Hadaschik, Jeremie Calais, Frederik L. Giesel, Robert Reiter, Tobias Maurer, Matthias Heck, Andrei Gafita, Michael J. Morris, Stefano Fanti, Wolfgang A. Weber, Thomas A. Hope, Michael S. Hofman, Wolfgang Peter Fendler, Matthias Eiber
Summary: This study proposes the PROMISE V2 framework for standardized interpretation and reporting of PSMA-PET findings, aiming to improve communication between imaging experts and uro-oncologists. The framework integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine and research.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Wolfgang A. Weber, Henryk Barthel, Frank Bengel, Matthias Eiber, Ken Herrmann, Michael Schaefers
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Volker Morath, Corinna Brandt, Friedrich-Christian Deuschle, Claudia T. Mendler, Birgit Blechert, Dominik Summer, Cyril Barinka, Clemens Decristoforo, Wolfgang A. Weber, Markus Schwaiger, Arne Skerra
Summary: Anticalin proteins targeting PSMA with tailored plasma half-life using PASylation technology are promising radioligands for PET imaging of xenograft tumors in mice. PET imaging using the FsC radiochelator is superior to Dfo radiochelator and adjusting the plasma half-life of Anticalin radioligands using PASylation technology can increase radioisotope accumulation within the tumor.
MOLECULAR PHARMACEUTICS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Borjana Bogdanovic, Esteban L. Solari, Alberto Villagran Asiares, Sandra van Marwick, Sylvia Schachoff, Matthias Eiber, Wolfgang A. Weber, Stephan G. Nekolla
Summary: This study aimed to determine the effects of different PSMA PET timing on signal kinetics and its correlation with patients' PSA and Gleason scores. The results showed that the detection of tumors remained unchanged in static and dynamic scans. The activity concentration trend of lesions in pelvic lymph nodes and bones was mostly negative, while lesions in the prostate and prostatic fossa showed a positive trend. The correlation between dynamic parameters and PSA varied depending on the radiotracer used.
EUROPEAN JOURNAL OF HYBRID IMAGING
(2023)
Article
Oncology
Carolin Kitzberger, Khuram Shehzad, Volker Morath, Rebekka Spellerberg, Julius Ranke, Katja Steiger, Roland E. Kaelin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, Rainer Glass, Wolfgang A. Weber, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Summary: New treatment strategies are urgently needed for glioblastoma (GBM) due to its resistance to standard treatment and poor prognosis. In this study, mesenchymal stem cells (MSCs) were engineered to express the sodium/iodide symporter (NIS) in response to interleukin-6 (IL-6) activation, and were successfully used to deliver NIS deep into the GBM tumor microenvironment. This novel tumor-targeted gene therapy approach resulted in enhanced radiotracer uptake, delayed tumor growth, and improved survival in mice with GBM.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Article
Medicine, Research & Experimental
Sabrina Kraus, Philipp Klassen, Malte Kircher, Alexander Dierks, Stefan Habringer, Alexander Gaeble, Klaus Martin Kortuem, Niels Weinhold, Valeeza Ademaj-Kospiri, Rudolf A. Werner, Andreas Schirbel, Andreas K. Buck, Peter Herhaus, Hans-Juergen Wester, Andreas Rosenwald, Wolfgang A. Weber, Hermann Einsele, Ulrich Keller, Leo Rasche, Constantin Lapa
Summary: This study evaluates the prognostic impact of splenic CXCR4 expression in patients with multiple myeloma (MM). The findings suggest that splenic Ga-68-Pentixafor uptake is associated with disease progression, treatment history, and clinical outcome. Reduced splenic uptake is linked to unfavorable prognosis and can serve as an independent predictor of survival.